amikacin + aztreonam

Amikacin + aztreonam is a combination of two antibiotics used primarily for the treatment of severe infections caused by multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa. Amikacin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing bacterial cell death. Aztreonam is a monobactam beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding protein 3 (PBP-3), leading to cell lysis and death. This combination may be used in clinical scenarios where synergistic antibacterial activity is desired or when treating organisms resistant to other therapies. The use of this combination has been reported in complex infections such as osteomyelitis due to metallo-beta-lactamase-producing Pseudomonas aeruginosa.